JP2024028651A5 - - Google Patents

Download PDF

Info

Publication number
JP2024028651A5
JP2024028651A5 JP2024010105A JP2024010105A JP2024028651A5 JP 2024028651 A5 JP2024028651 A5 JP 2024028651A5 JP 2024010105 A JP2024010105 A JP 2024010105A JP 2024010105 A JP2024010105 A JP 2024010105A JP 2024028651 A5 JP2024028651 A5 JP 2024028651A5
Authority
JP
Japan
Prior art keywords
mrna
composition
dnah5
liposome
lipids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024010105A
Other languages
English (en)
Japanese (ja)
Other versions
JP7789103B2 (ja
JP2024028651A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/012529 external-priority patent/WO2020146344A1/en
Application filed filed Critical
Publication of JP2024028651A publication Critical patent/JP2024028651A/ja
Publication of JP2024028651A5 publication Critical patent/JP2024028651A5/ja
Application granted granted Critical
Publication of JP7789103B2 publication Critical patent/JP7789103B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024010105A 2019-01-07 2024-01-26 原発性線毛機能不全症の治療のための組成物および方法 Active JP7789103B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962789414P 2019-01-07 2019-01-07
US62/789,414 2019-01-07
PCT/US2020/012529 WO2020146344A1 (en) 2019-01-07 2020-01-07 Composition and methods for treatment of primary ciliary dyskinesia
JP2021539435A JP2022516356A (ja) 2019-01-07 2020-01-07 原発性線毛機能不全症の治療のための組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021539435A Division JP2022516356A (ja) 2019-01-07 2020-01-07 原発性線毛機能不全症の治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2024028651A JP2024028651A (ja) 2024-03-04
JP2024028651A5 true JP2024028651A5 (cg-RX-API-DMAC10.html) 2025-01-15
JP7789103B2 JP7789103B2 (ja) 2025-12-19

Family

ID=69423424

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539435A Pending JP2022516356A (ja) 2019-01-07 2020-01-07 原発性線毛機能不全症の治療のための組成物および方法
JP2024010105A Active JP7789103B2 (ja) 2019-01-07 2024-01-26 原発性線毛機能不全症の治療のための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021539435A Pending JP2022516356A (ja) 2019-01-07 2020-01-07 原発性線毛機能不全症の治療のための組成物および方法

Country Status (8)

Country Link
US (3) US11559561B2 (cg-RX-API-DMAC10.html)
EP (1) EP3908597A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022516356A (cg-RX-API-DMAC10.html)
CN (1) CN113412273B (cg-RX-API-DMAC10.html)
AU (2) AU2020206109B2 (cg-RX-API-DMAC10.html)
CA (1) CA3125588A1 (cg-RX-API-DMAC10.html)
IL (1) IL284480A (cg-RX-API-DMAC10.html)
WO (1) WO2020146344A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3025626A1 (en) 2016-05-27 2017-11-30 Transcriptx, Inc. Treatment of primary ciliary dyskinesia with synthetic messenger rna
WO2020146344A1 (en) 2019-01-07 2020-07-16 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
EP4308703A4 (en) * 2021-03-19 2025-06-04 Recode Therapeutics, Inc. Polynucleotide compositions, associated formulations and methods of using the same
MX2023011227A (es) 2021-03-22 2023-12-06 Recode Therapeutics Inc Composiciones y metodos para administracion dirigida a celulas.
JP2024545572A (ja) * 2021-11-10 2024-12-10 トランスレイト バイオ, インコーポレイテッド 原発性線毛機能不全の治療のための組成物及び方法
WO2026042870A1 (ja) * 2024-08-23 2026-02-26 武田薬品工業株式会社 脂質ナノ粒子

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
EP1327684A1 (en) * 2002-01-14 2003-07-16 Universitätsklinikum Freiburg DNAH5 and its use in diagnosis
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
EP2049665A2 (en) 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
WO2008073661A2 (en) * 2006-11-09 2008-06-19 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
WO2009058911A2 (en) 2007-10-31 2009-05-07 Applied Biosystems Inc. Preparation and isolation of 5' capped mrna
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
BR112014024131A2 (pt) 2012-03-29 2017-07-25 Shire Human Genetic Therapies lipídios catiônicos ionizáveis
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
PL3122878T3 (pl) * 2014-03-24 2019-06-28 Translate Bio, Inc. TERAPIA mRNA DO LECZENIA CHORÓB OCZU
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3270894B1 (en) 2015-03-19 2021-02-24 Translate Bio, Inc. Mrna therapy for pompe disease
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
CA3025626A1 (en) 2016-05-27 2017-11-30 Transcriptx, Inc. Treatment of primary ciliary dyskinesia with synthetic messenger rna
US20180153822A1 (en) 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
CN116549671A (zh) 2016-11-10 2023-08-08 川斯勒佰尔公司 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
WO2018165257A1 (en) * 2017-03-07 2018-09-13 Translate Bio, Inc. Polyanionic delivery of nucleic acids
JP7256824B2 (ja) 2018-04-25 2023-04-12 エスリス ゲーエムベーハー 粒子状製剤用の凍結保護剤
WO2020146344A1 (en) 2019-01-07 2020-07-16 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia

Similar Documents

Publication Publication Date Title
JP2016535729A5 (cg-RX-API-DMAC10.html)
JP2023169139A5 (cg-RX-API-DMAC10.html)
JP2022516356A5 (cg-RX-API-DMAC10.html)
JP2016539916A5 (cg-RX-API-DMAC10.html)
US20250145577A1 (en) Stereochemically enriched compositions for delivery of nucleic acids
JP2019073557A5 (cg-RX-API-DMAC10.html)
US20250152739A1 (en) Composition and methods for treatment of ornithine transcarbamylase deficiency
JP2016534992A5 (cg-RX-API-DMAC10.html)
JP7408061B2 (ja) 切断可能な脂質
US12201677B2 (en) Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency
JP2016535738A5 (cg-RX-API-DMAC10.html)
JP2018511588A5 (cg-RX-API-DMAC10.html)
JP2017520563A5 (cg-RX-API-DMAC10.html)
AU2019201924B2 (en) Lipid nanoparticle compositions and methods for mrna delivery
JP7463006B2 (ja) ステロイド性部分を含むカチオン性脂質
JP2017518371A5 (cg-RX-API-DMAC10.html)
US20240009281A1 (en) Mrna therapy for pompe disease
JP2024105430A (ja) チオエステルカチオン性脂質
WO2020257611A1 (en) Cationic lipids comprising an hydroxy moiety
WO2020257716A1 (en) Tricine and citric acid lipids
US12564645B2 (en) Methods for treatment of methylmalonic acidemia
US10780183B2 (en) Messenger RNA therapy for the treatment of Friedreich's ataxia
US12370238B2 (en) Composition and methods for treatment of primary ciliary dyskinesia
JP2024545572A5 (cg-RX-API-DMAC10.html)
NZ727281B2 (en) Stereochemically enriched compositions for delivery of nucleic acids